August 1, 2011
A critical eye on Infuse use studies
A leading spine journal is casting a critical eye on industry-supported research that has led to widespread use of Medtronic's controversial bone growth product Infuse. The June 2011 issue of Spine Journal carries a strongly worded editorial about the trial designs, reporting bias, and peer review shortfalls that the authors say have promoted the product's widespread use, with "eventual life-threatening complications and deaths."
Free Daily News
- ACS conference charts bold future for surgical quality with data, teamwork, frontline innovation
- Surgical leaders urged to weigh risks, rewards of innovation with a critical eye
- Health systems report dramatic nurse retention gains through residency, development programs
- Surgical innovation redefines what is possible for advanced colorectal cancer
- CMS proposal to end inpatient only list draws strong industry response
- Fall deaths among older adults have tripled, prescription drugs under scrutiny
- AI could shrink drug discovery from years to months, expert says
- AI vendors bet on guaranteed ROI as competition with Epic intensifies
- AMA 2026 CPT code set expands with AI, remote monitoring, leg revascularization updates
- PACU initiative cuts emergency response times from 9 to 2 minutes
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement